...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Experimental and therapeutic medicine >Efficacy and safety of tiotropium bromide combined with budesonide/formoterol in the treatment of moderate to severe chronic obstructive pulmonary disease
【24h】

Efficacy and safety of tiotropium bromide combined with budesonide/formoterol in the treatment of moderate to severe chronic obstructive pulmonary disease

机译：噻托基溴化物与胚乳/福莫特罗的疗效和安全性在治疗中度至重度慢性阻塞性肺病中的治疗方法

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

With the increase of environmental pollution, chronic obstructive pulmonary disease (COPD) has become a serious health threat. In the present study, the efficacy and safety of inhalation therapy of tiotropium bromide combined with budesonide/formoterol were assessed in 180 patients with moderate to severe COPD (clinical trial registry no. ChiCTR1800017584). Patients were treated by inhalation of budesonide/formoterol (control group) or inhalation of tiotropium bromide combined with budesonide/formoterol (intervention group). The results indicated that after the treatment, the forced expiratory volume in 1 sec, the modified Medical Research Council scale, the 6-min walking distance and the St. George's Respiratory Questionnaire scores for quality of life were significantly improved in the two groups, while the improvements in the intervention group were more significant (all P0.05). There was no significant difference in body mass indices between the two groups during the course of the treatment (P=0.302). The difference in the risk of an acute exacerbation between the two groups was also not significant (P=0.238). The median time to the first acute exacerbation from the start of treatment in the intervention group (53 days; 25% quartile, 50 days; 75% quartile, 62 days) was significantly longer than that in the control group (37 days; 25% quartile, 23 days; 75% quartile, 39 days; P=0.042). The adverse reaction rates in the intervention and control groups were 14.4 and 10.0%, respectively, without any significant difference. In conclusion, inhalation treatment of tiotropium bromide combined with budesonide/formoterol significantly improves pulmonary function, exercise capacity and quality of life of patients with COPD compared with budesonide/formoterol inhalation alone, while the effect of reducing the acute attack risk requires further evaluation.
机译：随着环境污染的增加，慢性阻塞性肺病（COPD）已成为严重的健康威胁。在本研究中，在180例中度至严重COPD的180例患者中评估了噻托溴铵的吸入治疗噻托溴铵/蛋白质的疗效和安全性（临床试验登记号。CHICTR1800017584）。通过吸入水果苷/蛋白质（对照组）或吸入噻托尼亚溴化物与培发酚/福莫特酚（干预组）吸入患者。结果表明，治疗后，强制呼气量在1秒内，修改后的医学研究委员会规模，6分钟的步行距离和圣乔治的呼吸问卷质量评分在两组中显着改善，而且干预组的改善更重要（所有P <0.05）。在治疗过程中两组之间的体重指数没有显着差异（p = 0.302）。两组之间急性加剧风险的差异也不显着（p = 0.238）。从干预组治疗开始的第一次急性加剧的中位时间（53天; 25％四分位数，50天; 75％四分位数，62天）显着长于对照组（37天; 25％; 25％）四分位数，23天; 75％四分位，39天; P = 0.042）。干预和对照组中的不良反应率分别为14.4和10.0％，没有任何显着差异。总之，与单独的硫化灭菌/福特蛋白质吸入相比，吸入治疗噻托尼亚溴化苯甲醚/蛋白质/蛋白质的患者的肺功能，运动能力和生活质量，而降低急性攻击风险的效果需要进一步评估。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号